CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for NRX Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

NRX Pharmaceuticals Inc
1201 ORANGE STREET, SUITE 600
Phone: (484) 254-6134p:484 254-6134 WILMINGTON, DE  19801  United States Ticker: NRXPNRXP
Business Summary
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman, President & Chief Executive Officer RichardAckerman
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer Jonathan C.Javitt 68 10/7/2024 5/1/2021
Chief Financial Officer & Director Lori B.Wittman
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Dura Medical, LLC 1575 Pine Ridge Rd Naples FL United States

Business Names
Business Name
BRPA
BRPAU
Dura Medical, LLC
HOPE Therapeutics, Inc.
NRXP

General Information
Number of Employees: 2 (As of 12/31/2020)
Outstanding Shares: 23,769,901 (As of 8/18/2025)
Shareholders: 59
Stock Exchange: NASD
Federal Tax Id: 822844431
Fax Number: (302) 575-1642


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, September 13, 2025